Tebipenem Pivoxil (CAS 161715-24-8) Comprehensive User Guide
Table of Contents
1. Product Overview & Specifications
Key Parameters
| Parameter | Tebipenem Pivoxil | Comparable Carbapenems |
|---|---|---|
| CAS Number | 161715-24-8 | N/A |
| Molecular Formula | C₂₂H₃₁N₃O₆S | Varies by compound |
| Bioavailability | ≥90% (prodrug conversion) | 30-75% |
| Antimicrobial Spectrum | Gram-positive/-negative aerobes/anaerobes | Narrower spectrum |
2. Clinical Applications & Therapeutic Uses
Primary Indications
- Multidrug-resistant respiratory infections
- Complicated urinary tract infections (cUTI)
- Pediatric otitis media treatment
Mechanism of Action
As a carbapenem-class β-lactam antibiotic, Tebipenem inhibits bacterial cell wall synthesis through penicillin-binding protein (PBP) interaction with MIC₉₀ values ≤0.06-1 μg/mL against key pathogens.
3. Administration Protocols
Dosing Guidelines
| Patient Group | Dosage | Frequency |
|---|---|---|
| Adults | 150-300 mg | q12h |
| Pediatrics | 4-6 mg/kg | q12h |
4. Clinical Case Studies
Case 1: MDR Pneumonia Resolution
A 58-year-old male with ventilator-associated pneumonia caused by ESBL-producing Klebsiella pneumoniae showed clinical improvement within 72 hours of Tebipenem therapy (200mg q12h).
5. Verified Customer Implementations
PharmaCorp Solutions
Implemented Tebipenem in their anti-infective portfolio, reporting 92% pathogen eradication rate in Phase III trials for cUTI.
EuroHealth Partners
Reduced ICU infection mortality rates by 40% through prophylactic Tebipenem protocols in transplant patients.
6. Technical Consultation & Ordering
For COA/MSDS documentation or bulk pricing:
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。